Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1211-1217

  Johansson, David ^a   Johansson, Anders ^a   Grankvist, Kjell ^a   Andersson, Ulrika ^a   Henriksson, Roger ^a   Bergström, Per ^a   Brännström, Thomas ^a   Behnam Motlagh, Parviz ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b Clinical Chemistry   (Sweden)

Author keywords

Apoptosis; Gb3; Glioblastoma; MAP kinases; PPMP; Verotoxin 1

Indexed keywords

CASPASE 3; CASPASE 9; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; DEXTRO,LEVO THREO 1 PHENYL 2 PALMITOYLAMINO 3 MORPHOLINO 1 PROPANOL; FLUORESCEIN DIACETATE; GLOBOTRIOSYLCERAMIDE; GLUCOSYLCERAMIDE; GLYCOLIPID; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; SHIGA TOXIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VEROTOXIN 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IRRADIATION; MITOCHONDRIAL MEMBRANE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA DYSENTERIAE; SIGNAL TRANSDUCTION;

EID: 33751079605     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3173     Document Type: Article

References (38)

1. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 2001; 50:163-71.
2. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR. The treatment of malignant meningioma with verotoxin. Neoplasia 2002; 4:304-11.
3. Head SC, Karmali MA, Lingwood CA. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 1991; 266:3617-21.
4. Olsnes S, Sandvig K. How protein toxins enter and kill cells. Cancer Treat Res 1988; 37:39-73.
5. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT. Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992; 180:65-94.
6. Sandvig K, Grimmer S, Lauvrak SU, Torgersen ML, Skretting G, van Deurs B, Iversen TG. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol 2002; 117:131-41.
7. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171:45-50.
8. Gariepy J. The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol 2001; 39:99-106.
9. Saxena SK, O'Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 1989; 264:596-601.
10. Arab S, Murakami M, Dirks P, Boyd B, Hubbard SL, Lingwood CA, Rutka JT. Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. J Neurooncol 1998; 40:137-50.
11. Bhattacharjee RN, Park KS, Uematsu S, Okada K, Hoshino K, Takeda K, Takeuchi O, Akira S, Iida T, Honda T. Escherichia coli verotoxin 1 mediates apoptosis in human HCT116 colon cancer cells by inducing overexpression of the GADD family of genes and S phase arrest. FEBS Lett 2005; 579:6604-10.
12. Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, Terai A, Ogawa O, Yamamoto S. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol 2004; 171:1309-13.
13. Lee SY, Cherla RP, Caliskan I, Tesh VL. Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor receptor-independent mechanism. Infect Immun 2005; 73:5115-26.
14. Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res 1999; 11:33-9.
15. LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: Implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999; 94:2901-10.
16. Marcus DM, Kundu SK, Suzuki A. The P blood group system: Recent progress in immunochemistry and genetics. Semin Hematol 1981; 18:63-71.
17. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J. CD77: An antigen of germinal center B cells entering apoptosis. Eur J Immunol 1991; 21:1131-40.
18. Lingwood CA. Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996; 4:147-53.
19. Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J Cell Physiol 1998; 177:646-60.
20. Sandvig K, Ryd M, Garred O, Schweda E, Holm PK, van Deurs B. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 1994; 126:53-64.
21. Falguieres T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, Salamero J, Johannes L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell 2001; 12:2453-68.
22. Katagiri YU, Mori T, Nakajima H, Katagiri C, Taguchi T, Takeda T, Kiyokawa N, Fujimoto J. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem 1999; 274:35278-82.
23. Kovbasnjuk O, Edidin M, Donowitz M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco2 cells. J Cell Sci 2001; 114:4025-31.
24. Mori T, Kiyokawa N, Katagiri YU, Taguchi T, Suzuki T, Sekino T, Sato N, Ohmi K, Nakajima H, Takeda T, Fujimoto J. Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. Exp Hematol 2000; 28:1260-8.
25. Giese A, Westphal M. Treatment of malignant glioma: A problem beyond the margins of resection. J Cancer Res Clin Oncol 2001; 127:217-25.
26. Larsson R, Nygren P. A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 1989; 9:1111-9.
27. Jimeno A, Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol 2005; 53:179-92.
28. Abe A, Inokuchi J, Jimbo M, Shimeno H, Nagamatsu A, Shayman JA, Shukla GS, Radin NS. Improved inhibitors of glucosylceramide synthase. J Biochem (Tokyo) 1992; 111:191-6.
29. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol 1997; 6:133-42.
30. Mese H, Sasaki A, Alcalde RE, Nakayama S, Matsumura T. Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Chemotherapy 2000; 46:69-76.
31. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002; 2:277-88.
32. Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003; 6:129-41.
33. Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, Kane A, Donowitz M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci USA 2005; 102:19087-92.
34. Arab S, Russel E, Chapman WB, Rosen B, Lingwood CA. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol Res 1997; 9:553-63.
35. Lingwood CA. Verotoxin/globotriaosyl ceramide recognition: Angiopathy, angiogenesis and antineoplasia. Biosci Rep 1999; 19:345-54.
36. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
37. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001; 22:153-83.
38. Jia J, Alaoui-El-Azher M, Chow M, Chambers TC, Baker H, Jin S. c-Jun NH2-terminal kinase-mediated signaling is essential for Pseudomonas aeruginosa ExoS-induced apoptosis. Infect Immun 2003; 71:3361-70.